The efficacy of the healthy food containing an extract prepared from Actinidia arguta, in decreasing symptoms of pruritus in hemodialysis patients

The efficacy of the healthy food containing an extract prepared from Actinidia arguta, in decreasing symptoms of pruritus in hemodialysis patients - The efficacy of an water soluble extract prepared from Actinidia arguta in hemodialysis patients with pruritus

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012826

Enrollment

Registered

2014-01-12

Start date

2014-01-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pruritus in hemodialysis patients

Interventions

tablets contain an water soluble extract prepared from Actinidia arguta placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, Age: Men and women 20 years old and older 2, Hemodialysis patients with symptomatic pruritus

Exclusion criteria

Exclusion criteria: 1, Level of IgE in the blood: under 50 IU/mL 2, Patients with i-PTH of 500pg/ml and above in the past one month. 3, Patients who had parathyroidectomy in the past 6 months of int the study 4, Patients with allergy to kiwi fruits 5, Patients in asthma care. 6, Patients in the cancer treatment 7, Patients with a history of kidney transplant 8, Patients who are pregnant or to be pregnant within three months 9, Patients with severe mental disorder 10, Patients who are scheduled to commence of Nalfurafine Hydrochloride and/or Antihistamic drug of int. the study. 11, Patients who are unsuitable to the study at a physician's discretion

Design outcomes

Primary

Measure	Time frame
1, Evaluate the effect in decreasing symptoms of pruritus measured by VAS(Visual analogue scale). 2, Changes in the level of IgE in the blood 3, Changes in the number of eosinophils in the blood 4, Changes in the level of ECP (Eosinophil Cationic Protein)	—

Secondary

Measure	Time frame
1, Changes in the level of phosphorus and potassium 2, Changes in the level of intact-PTH 3, Changes in the value of blood test and urine test	—

Countries

Japan

Contacts

Public ContactYurina Ono

2014 PG3S Secretariat (c/o Amano Kinen Clinic) Secretariat

ymizuno@jmks-med.or.jp81525212788

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026